Usefulness of Alpha-GST in Liver Transplantation

Predictive Ability of Alpha-GST to Detect Graft Primary Dysfunction After Liver Transplantation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02451046

Acronym

GST-LT

Enrollment

100

Registered

2015-05-21

Start date

2014-03-31

Completion date

2015-10-31

Last updated

2015-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evidence of Liver Transplantation

Keywords

Liver transplantation, Primary dysfunction

Brief summary

The primary objective of this study was to evaluate the ability of plasma alpha-GST measurements in liver donor (at the time of organ removal) to predict primary dysfunction in liver recipient. The secondary objective was to study the relationship between alpha-GST levels in the plasma of the liver transplant recipient and early graft function recovery.

Detailed description

Graft primary dysfunction (PDF) after liver transplantation is enhanced by the increasing use of extended-criteria allografts. This complication is burdened with high mortality and morbidity rates among liver transplant recipients. Alpha-GST is a short-life hepatocyte enzyme that may be an interesting biomarker for liver injury. A recently developped ELISA technique may allow fast and easy measurement of alpha-GST plasma concentration (Fastpack IP α-GST Immunoassay, Qualigen Inc., Carlsbad, CA). This study aims to evaluate the ability of plasma alpha-GST measurements in liver donor to predict PDF in liver recipient. Methods: Observational study conducted in one center (Beaujon hospital, APHP, Clichy, France). Measurements of plasma levels of alpha-GST using Fastpack IP α-GST Immunoassay (Qualigen Inc., Carlsbad, CA) at the time of organ removal in liver donor and daily from day 0 to day 7 after liver transplantation in recipients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* age \> 18 years * undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France )

Exclusion criteria

* age \>70 years and \<18 years

Design outcomes

Primary

Measure	Time frame	Description
Primary dysfunction (PDF) of liver graft	First week	To evaluate the ability of plasma alpha-GST measurements in liver donor (at the time of organ removal) to PDF in liver recipient.

Secondary

Measure	Time frame	Description
Early graft function recovery.	First week	To study the relationship between alpha-GST levels in the plasma of the liver transplant recipient and early graft function recovery.

Countries

France

Contacts

Primary ContactCatherine Paugam-Burtz, MD-PhD

catherine.paugam@bjn.aphp.fr140875610

Backup ContactEmmanuel Weiss, MD

manuweiss@yahoo.fr603004193

Outcome results